D&D Pharmatech's DD01 Phase 2 MASH Trial Achieves Statistical Significance in All 48-Week Liver Biopsy Endpoints, Boosting Accelerated Approval Prospects
D&D Pharmatech announced 48-week liver biopsy results from its US Phase 2 trial of DD01 for MASH at the EASL conference, showing statistically significant improvements across all endpoints.
NASH resolution without worsening fibrosis: DD01 62.5% vs placebo 5.3% (p<0.001). This is a key endpoint for accelerated approval, complementing the previously reported 12-week primary endpoint (≥30% liver fat reduction: 75.8% vs 11.8%, p<0.0001).
Fibrosis improvement without worsening NASH: DD01 50.0% vs placebo 15.8% (p<0.05). Achievement of both endpoints: DD01 37.5% vs placebo 5.3% (p<0.05). Analysis limited to 35 patients meeting strict criteria.
Positive outlook for stock price: the histology data strengthens the case for FDA accelerated approval and market leadership in MASH. Clinical trial success probability (~10%) remains a risk, but the robust results across primary and secondary endpoints differentiate DD01.
[AI Comprehensive Analysis]The 48-week biopsy results significantly enhance the probability of regulatory approval and commercialization, but caution is warranted given the small analysis set (35 patients) and early stage. The upcoming CSR in Q3 and regulatory discussions will be key catalysts for the stock.
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related to Investment Decision (Clinical Trial Results) (Receipt of Topline Data from US Phase 2 Clinical Trial of DD01 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment)